208
Participants
Start Date
December 31, 2005
Primary Completion Date
June 30, 2008
Study Completion Date
April 30, 2009
ChimeriVax-WN02 Low Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
ChimeriVax-WN02 Medium Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
ChimeriVax-WN02 High Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
0.9% Saline solution
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
ChimeriVax-WN02 High Dose
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
0.9 % NaCl solution
Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
The Glennan Centre for Geriatrics and Gerontologyy, EVMS, Norfolk
Bio-Kinetic Clinical Applications, Inc., Springfield
PRA International Clinical Pharmacology Center, Lenexa
Idaho Infectious Diseases, PLLC, Idaho Falls
HOPE Research Institute, Phoenix
Sanofi Pasteur, a Sanofi Company
INDUSTRY